Markets:

Overview

News

Currencies

International

Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

81.28 +0.05 (+0.06%)

Streaming Delayed Price Updated: 1:30 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Looking for growth without the hefty price tag? Consider NASDAQ:HALO. ↗

December 16, 2024

NASDAQ:HALO, a growth stock which is not overvalued.

Via Chartmill

In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals. ↗

December 13, 2024

For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals.

Via Chartmill

(HALO) - Analyzing Halozyme Therapeutics's Short Interest ↗

December 11, 2024

Via Benzinga

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook ↗

November 22, 2024

Halozyme stock rises after withdrawing its €2B acquisition offer for Evotec, while reaffirming strong growth outlook for 2024.

Via Benzinga

While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. ↗

November 22, 2024

NASDAQ:HALO stands out as a growth opportunity that won't break the bank.

Via Chartmill

NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

November 22, 2024

Despite its impressive fundamentals, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains undervalued.

Via Chartmill

Breaking Down Halozyme Therapeutics: 10 Analysts Share Their Views ↗

November 20, 2024

Via Benzinga

Looking Into Halozyme Therapeutics's Recent Short Interest ↗

November 05, 2024

Via Benzinga

A Look Ahead: Halozyme Therapeutics's Earnings Forecast ↗

October 30, 2024

Via Benzinga

Unveiling 12 Analyst Insights On Halozyme Therapeutics ↗

October 25, 2024

Via Benzinga

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion ↗

November 15, 2024

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio.

Via Benzinga

Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday ↗

November 01, 2024

Via Benzinga

Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗

November 01, 2024

Via Benzinga

Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout. ↗

October 22, 2024

Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout.

Via Chartmill

Despite its growth, NASDAQ:HALO remains within the realm of affordability. ↗

October 11, 2024

Despite its growth, NASDAQ:HALO remains within the realm of affordability.

Via Chartmill

Despite its impressive fundamentals, NASDAQ:HALO remains undervalued. ↗

October 10, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.

Via Chartmill

Investors seeking growth at a reasonable cost should explore NASDAQ:HALO. ↗

November 01, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing good growth, while it is not too expensive.

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 31, 2024

Via Benzinga

Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents. ↗

October 31, 2024

For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals.

Via Chartmill

A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts ↗

October 04, 2024

Via Benzinga

NASDAQ:HALO is showing good growth, while it is not too expensive. ↗

September 19, 2024

Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced.

Via Chartmill

NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

September 19, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

(HALO) - Analyzing Halozyme Therapeutics's Short Interest ↗

September 13, 2024

Via Benzinga

NASDAQ:HALO is not too expensive for the growth it is showing. ↗

August 29, 2024

NASDAQ:HALO is showing good growth, while it is not too expensive.

Via Chartmill

Top 2 Health Care Stocks That May Plunge In August ↗

August 26, 2024

Via Benzinga

Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm

September 17, 2024

From Kaskela Law LLC

Via Business Wire

Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

September 13, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know ↗

September 13, 2024

Via Benzinga

NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

August 28, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO): good value for what you're paying.

Via Chartmill

How Is The Market Feeling About Halozyme Therapeutics? ↗

August 20, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.